PMA device
Carotid Wallstent Monorail Endoprosthesis
Boston Scientific Corp · Stent, Carotid (NIM, Class III) · First FDA decision Oct 23, 2008, newest Nov 19, 2024Carotid artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
1
Naming "Carotid Wallstent Monorail"
MAUDE reports
4
Brand "Carotid Wallstent Monorail", since 2015
PubMed studies
0
Mentioning "Carotid Wallstent Monorail"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Carotid Wallstent Monorail Endoprosthesis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Carotid Wallstent Monorail EndoprosthesisPMA supplement
P050019-S042 · Decided Nov 19, 2024 · 147 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent, carotid (NIM) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Carotid Wallstent Monorail", any status and sponsor, newest update first.
Boston Scientific CorporationPublic (BSX)
NCT00741091 · 1,097 participants · Start Dec 2008 · Primary completion Oct 2010
Device: Carotid WALLSTENT Monorail Endoprosthesis; FilterWire EZ™ System™ · For: Carotid Artery Disease
Sites: Birmingham, Alabama; Fairhope, Alabama; Phoenix, Arizona · 112 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Carotid Wallstent Monorail", and for the whole product code for context.
This brand
4 reports: 2 malfunction, 2 injury, 0 death
Whole product code NIM
2,799 reports: 1,699 malfunction, 994 injury, 98 death
Newest reports for this brand
- CAROTID WALLSTENT MONORAILMalfunction
2134265-2016-11119 · Received Dec 7, 2016
Device type: Stent, Carotid (NIM)
Device problem as coded: Break; Activation, Positioning or Separation Problem
Patient problem as coded: No Consequences Or Impact To Patient
3 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2273-2025 · Started Jul 7, 2025 · Posted by FDA Aug 8, 2025
Reason given: Certain batches are being removed due to an increase in complaints received in which physicians encountered greater than anticipated resistance while attempting to withdraw the stent delivery system (SDS) from the guidewire or embolic protection device (EPD) after successful stent deployment. The most serious...
Cause as FDA categorized it: Process change control · Device type: Stent, Carotid (NIM)
Published research
The most relevant PubMed records for "Carotid Wallstent Monorail"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NIM.
- XACT® Carotid Stent SystemAbbott Vascular, Inc. · PMA 2025
- ENROUTE Transcarotid Stent SystemBoston Scientific Corporation · PMA 2023
- Rx Acculink Carotid Stent SystemAbbott Vascular · PMA 2016
- Acculink Carotid Stent System and Rx Acculink Carotid Stent SystemAbbott Vascular · PMA 2017
- Roadsaver/CASPER Carotid Stent DeviceMicroVention, Inc. · PMA 2025
- Cartoid Wallstent Monorail EndoprosthesisBoston Scientific Corp · PMA 2012
- Protege Gps & Protege Rx Carotid Stent SystemsMedtronic Vascular, Inc. · PMA 2011
- Cordis Precise Nitinol StentCordis US Corporation · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.